je.st
news
ALLY Trial Demonstrates High Cure Rates for Investigational...
2014-11-08 23:40:51| Biotech - Topix.net
Bristol-Myers Squibb Company today announced late-breaking data from the landmark ALLY Trial investigating a ribavirin-free 12-week regimen of daclatasvir in combination with sofosbuvir in genotype 3 hepatitis C patients, a patient population that has emerged as one of the most difficult to treat. The results of the study, which showed sustained virologic response 12 weeks after treatment in 90% of treatment-nai 1 2ve and 86% of treatment-experienced patients, will be presented at The Liver Meeting 2014, the Annual Meeting of The American Association for the Study of Liver Diseases , in Boston, MA, November 7 - 11. "Both treatment nai 1 2ve and treatment experienced patients in the ALLY-3 study achieved high SVR rates.
Tags: high
rates
trial
cure
Category:Biotechnology and Pharmaceuticals